SOLENO THERAPEUT. DL-001 (6XC F) stock market data APIs
€57.8819
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
SOLENO THERAPEUT. DL-001 Financial Data Overview
Price chart is built with
Anychart
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Prev. Close
57.8819
Open
57.8819
High
57.8819
Low
57.8819
52 wk Range
38.36-76.65
Market Cap
3 093 M
Shares Outstanding
53 145 K
Revenue
32 657 K
EPS
-0.9
Beta
-2.718
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SOLENO THERAPEUT. DL-001 data using free add-ons & libraries
Get SOLENO THERAPEUT. DL-001 Fundamental Data
SOLENO THERAPEUT. DL-001 Fundamental data includes:
- Net Revenue: 32 657 K
- EBITDA: -184 315 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2022-06-30
- EPS/Forecast: -0.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SOLENO THERAPEUT. DL-001 News
New
Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
A downtrend has been apparent in Soleno Therapeutics, Inc. (SLNO) lately with too much selling pressure. The stock has declined 26% over the past four weeks. However, given the fact that it is now in ...
Are Legal Probes Shaping Trust in Soleno Therapeutics’ (SLNO) Drug Pipeline and Investor Relations?
In recent weeks, multiple law firms, including Bragar Eagel & Squire and the Rosen Law Firm, have launched class action investigations against Soleno Therapeutics following a short report by Scorpion ...
Soleno Therapeutics (SLNO) Falls Hard on Patient Death
We recently published 10 Stocks Melt Down in Hours. Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the worst performers on Wednesday. Soleno Therapeutics dropped for a second day on Wednesday, she...
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index falling 0.8% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
